Plasma renin activity and cardiovascular disease (CVD) incidence correlate closely in people with hypertension. The effects of angiotensin II (Ang II) on blood pressure (BP) are important in hypertensive patients; accumulating data suggest that the growth effects of Ang II in the cardiovascular system play a critical role in the development of atherosclerosis. Atherosclerosis development in hypertensive patients requires fundamental changes in endothelial structure and function. Key among the factors that may affect the endothelium is the renin-angiotensin-bradykinin system. Ang II, independent of other environmental and neurohormonal factors, mediates the vessel wall changes critical for the development of atherosclerotic disease. A strong correlation appears to exist between Ang II and CVD. Blockade of the renin-angiotensin system has a major impact on arterial structure and function independent of BP. Certain angiotensin-converting enzyme (ACE) inhibitors produce significant improvements in arterial compliance, which may yield a reduction in cardiovascular events. Blockade of the neurohormonal system may be a critical first-line approach to management of hypertension in an effort to prevent or reverse endothelial dysfunction. Moreover, the effects of ACE inhibition, in addition to its effect on BP, suggest that this therapeutic approach may be appropriate for managing patients at risk of CVD who do not yet have hypertension. The ideal antihypertensive agent should yield smooth, consistent BP control over the entire 24-hour period, both to avoid BP variability that places patients at increased risk of cardiovascular events and to offer protection during the vulnerable early morning hours when patients are well known to be at high risk.
Introduction
Hypertension is the most common risk factor for development of cardiovascular disease (CVD) and remains a major health-care problem, with one in five Americans (one in four adults) afflicted. 1 Nearly a third are not even aware that they have high blood pressure (BP). Abundant data indicate that as BP increases, so does the incidence of CVD. A metaanalysis of nearly half a million patients illustrated that this increase is nearly linear. 2 The goal of antihypertensive therapy is to reduce the incidence of CVD, including myocardial infarction and stroke. Therapy has yielded far greater success in reducing the incidence of stroke than of coronary heart disease. The incidence of stroke is reduced by nearly half with antihypertensive treatment; that for coronary heart disease is reduced by only 14%. 3 However, even in hypertensive patients in whom BP is controlled, the relative risk of dying is about 30% higher than in normotensive patients. 4 This suggests that in hypertensive patients there are factors beyond elevated BP that are responsible for this increased risk.
The greater risk may be explained in part by the coexistence of dyslipidemia, insulin resistance, glucose intolerance, and obesity. Hypertension occurs in isolation in fewer than 20% of patients. 5 This has led researchers to focus on hypertension not just as a 'disease of numbers,' but as a much more complex syndrome of cardiovascular risk factors ( Figure 1 ). [6] [7] [8] [9] [10] [11] [12] [13] All of these contribute to the development of CVD and should receive attention in the hypertensive patient. The greater the number of risk factors present, the greater the risk of a cardiovascular event. In particular, hypertension, hypercholesterolaemia, and altered glucose metabolism interact closely in accelerating atherogenesis.
Role of the renin-angiotensin system
A delicate balance exists between haemodynamic factors, serum lipids, platelets, and the blood vessel wall. 7 The renin-angiotensin system plays a crucial role in this cardiovascular homeostasis. It acts as a circulating hormonal system, a local endogenous tissue hormonal system, and a neurotransmitter and neuromodulator.
14 The functions include control of electrolyte balance, fluid volume, and systemic BP via the circulating endocrine system. 11 The kidneys produce renin in response to changes in renal perfusion or blood flow. Angiotensin-converting enzyme (ACE) catalyses the conversion of angiotensin I to angiotensin II (ANG II), a potent vasoconstrictor that elevates BP and stimulates secretion of aldosterone, a salt-retention hormone.
More than 30 years ago, Brunner 15 showed that patients with low circulating renin levels appear to be protected from CVD. Those with higher renin levels appeared to be at greater risk of CVD. This study was one of the first to recognize the reninangiotensin system as an important risk indicator for CVD. Then, a study by Alderman et al 16 showed that in patients matched for BP but with other risk factors such as smoking, dyslipidaemia, and diabetes, those with elevated renin levels are at much greater risk of CVD (Figure 2 ). 16 
Development of endothelial dysfunction
The work of Laragh et al, 17 examining the association between the renin-angiotensin-aldosterone system and the development of hypertension and cardiovascular disease, has been supported by subsequent work by Dzau, 18 Gibbons, 19 and others that has focused on the role of increased levels of tissue Ang II in vascular disease. Ang II has a profound effect on the endothelium, and these effects appear to have an impact on the development of CVD. The endothelium may be the organ system that bridges various cardiovascular risk factorshypertension, diabetes, congestive heart failure, elevated cholesterol-and the development of atherosclerotic disease. Perhaps the two most important effects of excessive Ang II on the endothelium are (1) endothelial dysfunction and (2) vascular hypertrophy, resulting in decreased compliance (Figure 3 ).
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A well-functioning endothelium acts as a barrier between circulating blood and the subendothelial space. Endothelial dysfunction occurs when there is an upset in the balance of vasoactive substances and growth factors and inhibitors in the endothelium; this balance regulates the structure and function of the vessel wall. When the endothelium is injured, low-density-lipoprotein cholesterol can enter the vessel wall. [21] [22] [23] There, it becomes oxidized and acts as an irritant, causing inflammation. This is the earliest form of atherosclerosis.
The injury also induces the endothelium to have procoagulant instead of anticoagulant properties and to form vasoactive molecules, cytokines, and growth factors. 7, 11, 21 The inflammatory response stimulates migration and proliferation of smooth muscle cells, which become intermixed with the area of inflammation to form an intermediate lesion. 11 These effects are schematized in Figure 4 . The other important effect of an imbalance in Ang II involves stiffening of the blood vessel wall, or decreased compliance. Arterial stiffening is the principal cause of increasing systolic pressure in ageing and in patients with arterial hypertension. Moreover, it appears that as a vessel becomes stiffer and less compliant, the progression of atherosclerosis increases. 24 Normal vascular homeostasis is maintained by a balance between vasoconstrictors, such as Ang II, and vasodilators, such as nitric oxide. 11 The characteristics of these local vasoactive mediators are listed in Table 1 . 11 The balance between Ang II and nitric oxide is crucial to a healthy endothelium. When Ang II is elevated, endothelial dysfunction begins. The imbalance toward Ang II by itself can cause many of the changes in the endothelium that set the atherosclerotic process in motion. By stimulating growth, Figure 3 The role of the renin-angiotensin system in the circulation and in tissue. The circulating renin-angiotensin system exerts shortterm regulation on cardiovascular homeostasis and the tissue renin-angiotensin system influences the cardiovascular system through long-term structural changes. Reproduced with permission from Dzau. it stimulates smooth muscle cell hypertrophy, which decreases compliance. Compliance refers to the means by which the structure and function of the arterial wall influence the relation between volume and pressure, such that in stiff, noncompliant vessels, a greater rise in BP is yielded by a smaller change in volume as compared with the same change in volume in a normally compliant system. 25 The vessel has the capacity to alter its geometry to accommodate these changes; this is termed vascular remodelling.
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There appears to be a correlation between circulating angiotensin levels and development of atherosclerosis. 17, 26 However, other factors can also influence this balance. For example, insulin appears to be very important in the formation and release of nitric oxide at the level of the endothelium. [27] [28] [29] When, as in the case of a person with insulin resistance, insulin interaction with the endothelium is reduced, insulin flow into endothelial cells is lessened, and nitric oxide activity is compromised, once again driving the balance in favour of Ang II and decreasing compliance.
Measuring arterial compliance
We assessed the changes in arterial compliance from the normotensive to hypertensive state. 30 This was done using the Windkessel model, a technique that analyses the arterial pulse wave contour to quantify proximal compliance (aorta and large vessels) and distal, or reflective, compliance (small arteries and arterioles). Proximal compliance was 24% lower among subjects with borderline hypertension compared with those with normal BP and 33% lower in those with established hypertension compared with those with normal BP; distal compliance was 58 and 61% lower, respectively ( Figure 5 ).
This study indicates that changes in vessel compliance occur primarily at the initiation of hypertension. As one moves from borderline to established hypertension, there is little further change in compliance in the small vessels and an even smaller change in compliance of the larger vessels. Thus, decreased compliance may be an early marker of hypertension and may be a determinant of cardiovascular prognosis. 25 The implication-that perhaps high-risk patients should be treated before the development of overt hypertension-is the subject of much scrutiny.
Cardioprotective effects of ACE inhibition
As the renin-angiotensin system plays such a large role in the development of hypertension and, subsequently, atherosclerosis, studies have examined whether blocking this system can prevent the onset of endothelial changes. In the tissue reninangiotensin system, Ang II causes the degradation of bradykinin, which stimulates nitric oxide production and prostaglandin release. ACE, which is identical to kininase II, also causes bradykinin degradation. Thus, ACE inhibition's benefits appear to be due to the resulting bradykinin accumulation. There is abundant information suggesting a role for ACE-inhibitor therapy in reducing myocardial hypertrophy, vascular hypertrophy, atherosclerosis progression, plaque rupture, and thrombosis after plaque rupture.
14,31-34 These effects may be expected to reduce the incidence of major cardiovascular events (Table 2) . 14 In an experimental study, Clozel et al 31 studied spontaneously hypertensive rats given the longacting ACE inhibitor cilazapril compared with spontaneously hypertensive rats given placebo; a reference group of Wistar-Kyoto rats was also given placebo. At 14 weeks, the arteries were examined. The researchers found that cilazapril normalized the media thickness:diameter ratio in all types of arteries examined (carotid, mesenteric, renal, and coronary). Cross-sections of the arteries of the placebo-treated rats showed a stiffened vessel with many inflammatory cells-atherosclerosis at work. Thus, changes in the arterial wall were decreased or prevented with ACE inhibition. Studies in humans are consistent with these findings. Asmar et al 32 studied 16 patients with sustained hypertension before and 3 months after therapy with the ACE inhibitor perindopril. There was an impressive improvement in arterial compliance after 3 months. ACE inhibition also induced regression of left ventricular hypertrophy. At that point, the investigators started treating the patients with placebo. After 4 weeks, compliance returned toward baseline levels, demonstrating a reversal of the changes in the vessel wall achieved with ACE inhibition. Also, after discontinuing treatment, enddiastolic volume returned toward basal values. Thus, the disease process is reversible-as is the benefit when ACE-inhibitor therapy is discontinued.
Sihm et al 33 examined the effects of the ACE inhibitor perindopril on peripheral vascular structure and cardiac hypertrophy in patients with newly diagnosed hypertension and sought to determine whether there are any parallels between cardiac and vascular structural normalization. Gluteal subcutaneous biopsy specimens were examined at baseline and after 9 months of treatment with perindopril. Media:lumen ratio was measured in two small resistance arteries, and left ventricular mass was determined by echocardiography at baseline and after 12 months of treatment with perindopril.
Mean media:lumen ratio decreased significantly and left ventricular mass decreased significantly, both indicating improvement with perindopril treatment. The researchers concluded that perindopril normalizes both resistance artery structure and left ventricular hypertrophy in patients with hypertension within 1 year of treatment.
Mechanism of improvement
The decrease in BP alone does not appear to be the reason for the improvement in endothelial function. Studies that have compared ACE-inhibitor therapy with other classes of antihypertensive therapy suggest that ACE inhibition is the reason. Thybo et al 34 compared the effects of antihypertensive treatment on small arteries of patients with previously untreated hypertension. These investigators compared the effects of the b-blocker atenolol vs perindopril. While the decrease in BP yielded by the two agents was approximately the same, patients treated with atenolol showed no change in arterial compliance, whereas those treated with perindopril showed an increase in small-artery diameter and a reduction in the media:lumen ratio ( Figure 6 ). 34 The change in small-artery morphology caused by perindopril was not accompanied by any change in media cross-sectional area, suggesting that the change was due to remodelling-and suggesting that ACE inhibition was responsible for this normalization. Angiotensin-receptor blockers (ARBs) have BP-lowering effects similar to those of other antihypertensives, and recent studies, including the Irbesartan Diabetic Nephropathy Trial (IDNT), the Reduction of Endpoints in NIDDM with the Ang II Antagonist Losartan Study (RENAAL), and the Irbesartan Microalbuminuria Type 2 (IRMA 2) trial suggest that these agents also confer benefits beyond BP lowering. 35 Trials are under way that may further clarify this. The use of ARBs is accompanied by lower rates of cough and angioedema than seen with ACE inhibitors, presumably due to the ARBs' lack of effect on bradykinin levels.
Blood pressure variability and arterial compliance
Although many benefits of ACE inhibition in the hypertensive patient are now established, it should be noted that not all ACE inhibitors are created equal. Most desirable is an agent that provides smooth BP control over 24 h to avoid lability of BP.
Variability in BP appears to be very important in the development of atherosclerotic disease and in changes in arterial compliance. Studies show that the greater the diastolic load-the amount of time during the day that one is hypertensive-the greater the left ventricular mass index. Using ambulatory BP monitoring, White et al 36 showed that if more than 40% of ambulatory BP values were elevated over a 24-h period, the incidence of increased mass or decreased filling was 461%; if o40% of the ambulatory values were elevated, the incidence of these findings was o17%.
In another study conducted using ambulatory BP monitoring, Frattola et al 37 separated patients into 38 showed yet another problem with BP variability. Using simultaneous Holter (ambulatory electrocardiographic) and ambulatory BP monitoring, they found that changes in BP at any time of the day were clearly associated with periods of silent myocardial ischemia. Thus, smooth control of BP is essential, a finding that takes on even more importance in view of the knowledge that the peak incidences of cardiovascular events is in the early morning. 3 An effective 24-h control is crucial.
A once-daily drug is preferred because it facilitates patient adherence. In addition to this, if an agent indeed provides sustained and smooth BP control, it averts the intermittent BP surges that occur with the multiple doses of a shorteracting drug. Administration of multiple doses of a shorter-acting drug to effect coverage over a 24-h period would yield a 'sawtooth' pattern of decreased/elevated BP surges, surges similar to the early morning surge known to increase the risk of coronary events and stroke. The choice of ACE inhibitor may be particularly important because within the ACE-inhibitor class, agents vary dramatically in duration of action.
The trough-to-peak ratio (T:P) is the parameter by which the US Food and Drug Administration (FDA) evaluates a drug for once-daily status. The T:P measures the percentage of BP-lowering effect achieved at peak that is still in effect at trough (24 h after dosing). Thus, a 50% T:P indicates that 50% of the BP reduction effect achieved at peak is in effect 24-h postdose ( Figure 7) . The higher the T:P, the more constant the effect of the drug through the 24-h dosing period. In addition, a high T:P insures that a drug does not lose efficacy immediately before the next dose administration, which typically occurs in the morning, when cardiovascular risk is high.
A X50% T:P is required by the FDA for a oncedaily drug. Agents with higher T:Ps are lisinopril (30-70%), trandolapril (50-90%), and perindopril (75-100%) (Figure 8) . [40] [41] [42] [43] [44] [45] [46] The half-life of an agent should also be considered; a once-daily agent with a shorter half-life that is given at a lower dosage may not, in effect, be a once-daily drug. For example, the T:P of lisinopril is 24% at 2.5 mg and 55% at 80 mg. 47 While the significance of the T:Ps of ACE inhibitors have not been evaluated in clinical outcome studies, consistent, effective control over the entire 24-h period is desirable.
Summary
Hypertension comprises a complex syndrome of cardiovascular risk factors. The interaction of these risk factors compound the risk of a cardiovascular event. Therefore, if physicians are truly to make an impact in reducing the risk of a cardiovascular event, they must treat more than simply the elevated BP. The physician should consider the presence of these risk factors and attempt to treat as many aspects of the syndrome as is possible. Use of an ACE inhibitor will have a beneficial effect not only on hypertension, but on vascular homeostasis, which is a pivotal factor in the initiation and progression of atherosclerosis. The ideal antihypertensive agent should yield smooth, constant BP control over the entire 24-hour period, both to avoid the variability in BP that places patients at increased risk of cardiovascular events and to offer protection [40] [41] [42] [43] [44] [45] [46] [47] 
